Do N-of-1 Trials Need IRB Review?

Abstract

There is no standard policy regarding the regulatory or institutional approval of N-of-1 trials in the United States. The objective of this study was to examine whether institutional review boards (IRBs) accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) consider N-of-1 trials as meeting the definition of human subjects research (45CFR46.102) and requiring IRB approval. A questionnaire was distributed via email to 170 AAHRPP-accredited IRBs in the United States. Responses were analyzed using statistical and qualitative methods. Nineteen of 59 respondents reported viewing N-of-1 trials as research. Twelve respondents reported having a policy regarding N-of-1 trials, and in all cases, such policies did not consider N-of-1 trials as meeting the definition of research. This topic deserves wider examination in the IRB literature and community to inform policies and guidance as N-of-1 trials become more common in the pursuit of personalized, precision medicine.

Keywords

research ethics IRB (institutional review board)human subjects research biomedical research

Get full access to this article

View all access options for this article.

References

Agency for Healthcare Research and Quality Effective Health Care Program. (2014). Design and implementation of N-of-1 trials: A user’s guide (Research report–Final). Retrieved from http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1844&pageaction=displayproduct

Duan

Kravitz

R. L.

Schmid

C. H.

(2013). Single-patient (n-of-1) trials: A pragmatic clinical decision methodology for patient-centered comparative effectiveness research. Journal of Clinical Epidemiology, 66, 21-28.

Gabler

N. B.

Duan

Vohra

Kravitz

R. L.

(2011). N-of-1 trials in the medical literature: A systematic review. Medical Care, 49, 761-768.

Hay

M. C.

Weisner

T. S.

Subramanian

Duan

Niedzinski

E. J.

Kravitz

R. L.

(2008). Harnessing experience: Exploring the gap between evidence-based medicine and clinical practice. Journal of Evaluation in Clinical Practice, 14, 707-713.

Lillie

E. O.

Patay

Diamant

Issell

Topol

E. J.

Schork

N. J.

(2011). The n-of-1 clinical trial: The ultimate strategy for individualizing medicine? Personalized Medicine, 8, 161-173.

Nikles

C. J.

Glasziou

P. P.

Del Mar

C. B.

Duggan

C. M.

Mitchell

(2000). N of 1 trials. Practical tools for medication management. Australian Family Physician, 29, 1108-1112.

Nikles

C. J.

Mitchell

G. K.

Schluter

Good

Hardy

Rowett

. . . Currow

(2011). Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: The case of palliative care. Journal of Clinical Epidemiology, 64, 471-480.

Punja

Eslick

Duan

Vohra

(2014). An ethical framework for N-of-1-Trials: Clinical care, quality improvement, or human subject research? In Gabler

. (Eds.), Design and implementation of N-of-1 trials: A user’s guide (AHRQ Publication No. 13(14)-EHC122-EF) (pp. 13-22). Rockville, MD: Agency for Healthcare Research and Quality.

Senior

H. E.

Mitchell

G. K.

Nikles

Carmont

S. A.

Schluter

P. J.

Currow

D. C.

. . . Hardy

J. R.

(2013). Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: A rationale and protocol. BMC Palliative Care, 12(1), Article 17.

10.

Zucker

D. R.

Ruthazer

Schmid

C. H.

(2010). Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: Methodologic considerations. Journal of Clinical Epidemiology, 63, 1312-1323.

11.

Zucker

D. R.

Schmid

C. H.

McIntosh

M. W.

D’Agostino

R. B.

Selker

H. P.

Lau

(1997). Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. Journal of Clinical Epidemiology, 50, 401-410.